A vaccine designed to treat breast cancer appeared to be safe in women with advanced disease and showed signs of actually slowing down tumors, U.S. researchers reported on Friday.
Dendreon Corporation, maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called her2/neu-positive breast cancer, which affects between 20 percent and 30 percent of breast cancer patients.Like Provenge, Neuvenge is made using immune cells from the cancer patient, so it is a tailor-made vaccine.
SOURSE - Washington Post
| Tags: Breast Cancer, Cancer, Public Health and Safety, Women's Health |
Labels: Breast Cancer, Cancer, Prostate Cancer, Public Health, Women's Health